Aspira Pathlab

  • Market Cap: Micro Cap
  • Industry: Healthcare Services
  • ISIN: INE500C01017
  • NSEID:
  • BSEID: 540788
INR
131.00
-4.65 (-3.43%)
BSENSE

Nov 20

BSE+NSE Vol: 766

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 1002885,
    "name": "Aspira Pathlab",
    "stock_name": "Aspira Pathlab",
    "full_name": "Aspira Pathlab & Diagnostics Ltd",
    "name_url": "stocks-analysis/aspira-pathlab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "131.00",
    "chg": -4.65,
    "chgp": "-3.43%",
    "dir": -1,
    "prev_price": "135.65",
    "mcapval": "140.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540788,
    "symbol": "",
    "ind_name": "Healthcare Services",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE500C01017",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": 766,
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/aspira-pathlab-1002885-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Aspira Pathlab & Diagnostics Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-sell-4267869",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/AspiraPathlabDi_mojoScore_4267869.png",
        "date": "2026-11-19 10:10:57",
        "description": "Aspira Pathlab & Diagnostics Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 18 May 2026, reflecting a shift from a previous 'Strong Sell' stance. However, the analysis and financial metrics discussed here represent the company’s current position as of 19 November 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-sell-4245480",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/AspiraPathlabDi_mojoScore_4245480.png",
        "date": "2026-10-31 10:10:03",
        "description": "Aspira Pathlab & Diagnostics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 31 October 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance."
      },
      {
        "title": "Aspira Pathlab Gains 0.95% Despite Sensex Fall: 4 Key Factors Driving the Move",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/aspira-pathlab-gains-095-despite-sensex-fall-4-key-factors-driving-the-move-4212664",
        "imagepath": "",
        "date": "2026-10-03 13:01:26",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>28 Sep:</strong> Stock surges 5.00% amid broad market weakness</p>\n                    <p><strong>29 Sep:</strong> Aspira Pathlab hits new 52-week and all-time high at Rs.143.34</p>\n                    <p><strong>30 Sep:</strong> Stock reaches fresh 52-week and all-time high at Rs.149.99</p>\n                    <p><strong>1 Oct:</strong> Profit-taking leads to 4.74% decline, closing at Rs.131.25</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.136.52</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=..."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Aspira Pathlab & Diagnostics Ltd to 52-Week High of Rs 149.99",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/aspira-pathlab-diagnostics-ltd-hits-new-52-week-high-at-rs14999-4209504",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AspiraPathlabDi_priceRelatedfactors_4209504.png",
        "date": "2026-09-30 09:48:36",
        "description": "Surging past its previous peaks, Aspira Pathlab &amp; Diagnostics Ltd touched a new 52-week high of Rs 149.99 on 30 Sep 2026, marking a remarkable 130.47% gain over the past year. This milestone comes amid a backdrop of strong technical momentum that has propelled the micro-cap healthcare services stock well ahead of the broader market’s subdued performance."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Ltd Hits All-Time High of Rs 149.99 as Momentum Builds Across Timeframes",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/aspira-pathlab-diagnostics-ltd-hits-all-time-high-at-rs14999-4209432",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AspiraPathlabDi_priceRelatedfactors_4209432.png",
        "date": "2026-09-30 09:36:15",
        "description": "Extending its winning streak to four sessions, Aspira Pathlab & Diagnostics Ltd surged to a fresh all-time high of Rs 149.99 on 30 Sep 2026, outperforming its healthcare services sector peers and the broader Sensex by a wide margin."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Ltd Hits All-Time High of Rs 143.34 as Momentum Builds Across Timeframes",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/aspira-pathlab-diagnostics-ltd-hits-all-time-high-at-rs14334-4208033",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AspiraPathlabDi_priceRelatedfactors_4208033.png",
        "date": "2026-09-29 09:34:52",
        "description": "Extending its winning streak to three sessions, Aspira Pathlab & Diagnostics Ltd surged 5% today to touch a fresh all-time high of Rs 143.34, significantly outperforming the Healthcare Services sector and the broader Sensex."
      },
      {
        "title": "Aspira Pathlab &amp; Diagnostics Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-sell-4207191",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AspiraPathlabDi_mojoScore_4207191.png",
        "date": "2026-09-28 10:10:05",
        "description": "Aspira Pathlab &amp; Diagnostics Ltd is rated Sell by MarketsMOJO. This rating was last updated on 18 May 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 28 September 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Ltd Gains 13.06%: 2 Key Milestones Drive the Rally",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/aspira-pathlab-diagnostics-ltd-gains-1306-2-key-milestones-drive-the-rally-4205846",
        "imagepath": "",
        "date": "2026-09-26 13:01:31",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>21 Sep:</strong> Stock opens week at Rs.120.75, surging 5.00%</p>\n                    <p><strong>22 Sep:</strong> Continues strong gains, closing at Rs.126.78 (+4.99%)</p>\n                    <p><strong>23 Sep:</strong> Hits Rs.133.11 (+4.99%), technical bullishness confirmed</p>\n                    <p><strong>24 Sep:</strong> Reaches new 52-week and all-time high of Rs.138.99</p>\n                    <p><strong>25 Sep:</strong> Week closes at Rs.130.02, marginal gain of 0.04%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\">\n                        <div class=\"stat-label\">Week Open</div>\n                        <div cla..."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Aspira Pathlab & Diagnostics Ltd to 52-Week High of Rs 138.99",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/aspira-pathlab-diagnostics-ltd-hits-new-52-week-high-of-rs13899-4203275",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AspiraPathlabDi_priceRelatedfactors_4203275.png",
        "date": "2026-09-24 09:49:16",
        "description": "Surging to a fresh 52-week and all-time high of Rs 138.99 on 24 Sep 2026, Aspira Pathlab &amp; Diagnostics Ltd has demonstrated remarkable price momentum, rallying over 44.5% in just the past 10 trading sessions. This impressive run has propelled the stock well above all key moving averages, underscoring a strong technical foundation amid a broader market environment that remains subdued."
      }
    ],
    "total": 52,
    "sid": "1002885",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/aspira-pathlab-diagnostics-1002885"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "18-Nov-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jay Arvind Bhanushali",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "14-Nov-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jay Arvind Bhanushali",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "14-Nov-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jay Arvind Bhanushali",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

18-Nov-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jay Arvind Bhanushali

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

14-Nov-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jay Arvind Bhanushali

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

14-Nov-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jay Arvind Bhanushali

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available